By Brian Marckx, CFA
Q4 Financials, Business Update
Q4 Financials: Record Product Revenue, Record-Implying Guidance, Several Catalysts To Ramp 2014…
CytoSorbents (CTSO) reported results for the fourth quarter ending December 31, 2013 and as expected following the Q4 revenue pre-announcement in mid-January, product sales came in at an all-time high with total revenue missing the quarterly record by less than $2k. While product sales came in about $16k shy of the low range of $330k - $360k expected with the pre-announcement (management noted on the call that ~$37k of orders expected to be recognized in Q4 were pushed back to Q1 2014), they jumped 54% sequentially, were up 257% from the same period in 2012 and accounted for 38% of the total product sales for all of 2013.
Importantly, product sales have increased on a sequential basis every quarter except one since Q3 2012. Additionally, comments on the call indicate management expects product sales to maintain or even accelerate this momentum throughout 2014. This includes Q1 2014 guidance.for product sales in the range of $530k - $570k (sequential growth of 75% - 82%) and 2014 full-year total revenue potentially being “multiples” of the $857k generated in 2013. We model a sequential uptick in revenue throughout 2014 as near-term catalysts, including several of those that management outlined on the call, make an increasing contribution over time.
And while there’s still potential to see some quarterly volatility, we think it is now clear that follow-on orders from existing customers (where the majority of orders are coming from – which we view as particularly positive), use of CytoSorb in an expanded number of critical care applications and in broadening of the geographic commercialization footprint are all contributing to the consistent sequential revenue growth. Awareness-building, clinical data and case studies outlining successful interventions with CytoSorb has been at the heart of CTSO’s sales efforts, the fruits of which are being seen in the consistent product revenue growth. CTSO will continue to build on this in 2014 and with the launch of the patient registry documenting real-world successful interventions with CytoSorb, the bulk of clinical evidence will continue to grow which should further enable the marketing message.
Q4 total revenue was $879k, up 46% yoy and flat from Q3 2013. Revenue consisted of $314k in product sales and approximately $249k and $316k in DARPA and other grant revenue, respectively. For the full year, revenue increased 80% to $2.4M and consisted of $822k (+442% yoy) in product sales and approximately $1.1M and $479k in DARPA and other grant revenue, respectively.
In addition to expected significant growth of product sales in 2014, CTSO will also be booking additional grant revenue. As of the close of 2013 up to approximately $1.6M remains to be billed under the DARPA grant as does about $375k of the Phase II SBIR contract and ~$100k of the NHLBI Ph 1 HemoDefend grant. And the company has yet to bill anything under the USAF funded rhabdomyolysis study, valued at about $3M, and which just recently commenced.
Product gross margins were 54% and 61% in Q4 and the full year 2013, respectively, compared to 55% and 46% in the year-earlier periods. Total gross margin, which is less reflective of the core business and is impacted by grant-related R&D expenses being captured in COGS, was 5% and 21% in Q4 and the full-year 2013. Q4 operating expenses were $1.1M, well below our estimated $1.4M estimate – the difference related to lower R&D expenses (which were just $32k – and again, reflects grant-related R&D being captured in COGS), partially offset by higher than modeled SG&A expense.
Q4 net income and EPS were ($1.8) million and ($0.01), in-line with our ($1.8) million and ($0.01) estimates. For the full-year, net income and EPS were ($7.1) million and ($0.03).
Cash used in operating activities was $1.1M and $3.5M in Q4 and the full-year, respectively. CTSO exited 2013 with $2.2M in cash and equivalents. Subsequent to year-end the company raised gross proceeds of $10.2M through the issuance of 40.8M common shares (@ $0.25) with 50% warrant coverage (5-year, $0.3125 exercise price).
We are maintaining our Outperform rating on shares of CTSO. Based on our 10-year DCF model, we value the company at $0.50/share. See below for access to our full update on CTSO.
Putting The Cash To Work…
A key topic on the Q4 call was that CTSO will be putting the recent cash raise to work in specific areas to add another layer of growth. This includes additions to the sales force (particularly for the German market), additional distribution agreements (up to 5 more distributors in 2014) and partnerships, hiring of support personnel to help communicate the clinical successes of CytoSorb, adding to their clinical support staff and generation of more clinical data. Repeated was the message that they will be discerning in expanding geographically and will focus on areas that accept the CE Mark and with favorable reimbursement. Case reports of positive patient outcomes and additional clinical data is expected to help facilitate sales efforts within their existing footprint and will support efforts to establish reimbursement in countries that CTSO may look to enter.
CTSO also will look to use the funding to initiate a U.S. study for CytoSorb – not in the previously expected application for sepsis, but instead for cardiac surgery. On the call Dr. Chan laid out a compelling case for the reasons to pursue cardiac surgery (an application where CytoSorb has already had documented successes overseas) instead of sepsis in the U.S. – which we discuss further below.
CTSO Expects a Busy 2014…
The cash infusion provides CTSO with new options for growth. Dr, Chan mentioned on the call that, “Instead of doing what we need to do, we now have the capital resources to do what we want to do and what is right for the business in order to build shareholder value, as well as grow our business more rapidly.”
The company already has a game-plan and dedicated much of their earnings call to discussion of it. We list many of the highlights below.
- Beefed-up distribution: as of the end of 2013 CTSO had five distributors (covering parts of the UK, Ireland, The Netherlands, Turkey and Russia) plus the partnership with Biocon covering India. CTSO expects to add up to five additional distributors in 2014 in areas of the world (ex-Germany where they have a direct sales force) that accept the CE Mark (which is essentially all of Europe as well as other areas of the world).
CTSO will also look for other partnership arrangements similar to the one with Biocon, a relationship that appears to be mutually beneficial. In fact Biocon noted on their Q3 2013 earnings call (Jan. 23, 2014) that, “Our recent launches Alzumab and CytoSorb have done extremely well, with strong uptake from both doctors and patients.” Biocon appears to be solidly behind promoting CytoSorb, both from the clinical evidence side as well as feet on the ground. CTSO noted that Biocon will create a dedicated sales force for CytoSorb which will be focused on building awareness and educating physicians on use of the device. Biocon will also be setting up a patient registry and use case studies in promotion of the device and to develop manuscripts. We think additional partnerships similar to the one with Biocon can add meaningfully to CTSO’s results.
- Beefed-up sales force: as of the end of 2013 CTSO had four sales people selling direct in Germany, Austria and Switzerland. With just this skeleton crew, CTSO was able to ramp product sales to more than $800k in 2013 and established a presence with more than 100 key opinion leaders. CTSO expects to increase the sales force to 10 reps by the end of 2014 and has already brought on three additional reps since the end of 2013 – the direct sales force will continue to have a majority focus on Germany. And with cardiac surgery now a major focus (as is sepsis), CTSO has recently hired reps with contacts specifically in the cardiac surgery space.
- Drive utilization: CTSO first outlined their general plans to increase adoption and drive utilization last summer. Noting that while their initial sales strategy had focused almost exclusively on "cast(ing) a wide net" to broaden awareness and get hospitals and doctors interested in the device, that they would now also place a greater emphasis on penetration within the critical departments which have already been introduced to the technology in order to increase adoption and utilization. CTSO indicated on the call that they have already had successes in this regard – where CytoSorb may have been introduced to a particular hospital by a KOL and used in his or her intensive care specialty, but is now being used by other intensive care units within the same hospital.
- Clinical data: clinical outcomes data has been a driving force in accelerating product sales. CTSO will dedicate more resources towards additional studies and expects to have a regular flow of outcomes data coming from the various investigator initiated studies. A patient registry, case studies (on the call Dr. Chan highlighted several successful outcomes when CytoSorb was introduced with critically ill patients) and additional support personnel to help communicate the successes of CytoSorb along with presentations and publications will all be major focuses in 2014 to build awareness, drive adoption, increase sales and to support reimbursement.
Approximately 30 investigator initiated studies are ongoing as is the sepsis dosing study. In late December CTSO announced preliminary results from the dosing study. Results showed no serious device-related adverse events and demonstrated removal of cytokines throughout the 24hr treatment period in the 28 patients enrolled in the 24hrs/7days treatment arm. The other treatment arm (6hrs/up to 14 days) is currently enrolling patients. Assuming positive results, CTSO game plan now is to move to a larger study in sepsis in Germany.
Among the 30 investigator initiated studies, 11 relate to cardiac surgery. CTSO expects two of these controlled studies to be completed by Q3 (or earlier) of this year. Six other studies are using the device in septic shock, severe sepsis and lung injury – one of which should also complete this year. The other studies include patients with liver disease, trauma, burn injuries and acute pancreatitis. Data from these studies offer potential catalysts that can positively impact the marketing message and rate of adoption and utilization of CytoSorb.
- Presentations, conferences, user-meetings: another key to CTSO’s awareness-building efforts have been attendance and presentations at industry conferences. This will be an ongoing focus. Recently CTSO held its first Users Meeting at the DIVI conference in Germany which allows attendees to hear success stories directly from users the device. Comments at the Users Meeting included that physicians could “see the therapy turning the patient around”. CTSO noted that they have had impressive attendance at presentations at recent industry conferences.
- U.S. study: CTSO previous game-plan relative to the U.S. market was to use the European sepsis dosing trial data as support for FDA approval to run a sepsis trial in the U.S. On the Q4 call, however, CTSO said that they are now focused on running a pivotal trial in the U.S. for cardiac surgery. The reasons for focusing on cardiac surgery include the demand (and clinical successes) that CytoSorb has had in that application in Europe and CTSO believes cardiac surgery represents a faster regulatory approval timeline and will be lower cost and have less risk of failure than a sepsis related trial. For one, CTSO noted that outcomes are more predictable with cardiac surgery than with sepsis. Also, mortality will not be an endpoint in cardiac surgery – whereby it is with sepsis and is a relatively high hurdle. The cardiac surgery focus for the U.S. makes sense in that it is a relatively lower-risk endeavor and can get CytoSorb’s foot in the domestic door – the company can then focus on expanding the label to encompass additional indications. It also likely puts the device on the U.S. market and generating revenue here earlier than would have been the case if CTSO had pursued sepsis as the initial indication.
In addition, while there are currently blood-filtration products on the market that are used during cardiac surgery to reduce inflammatory substances, they do not target cytokines – which offers CytoSorb a wide-open market opportunity. While cardiac surgery was barely mentioned just 18 months ago, this seems to have quickly become a major driver of demand and interest in CytoSorb – with CTSO noting that 22 cardiac surgery centers have either used the device or expressed interest in doing so – this is up from just 10 in 2013. CTSO also indicated that based on interest that they’ve seen for the cardiac surgery application that specifically changed some of their sales efforts to dedicate more focus on cardiac surgery.
And while the market for cardiac surgery, at approximately $500M in the U.S.(per CTSO estimates), is likely significantly smaller than for sepsis (potentially 1+billion dollars), it still represents a relatively large target market. And, again, the company would likely look to expand the label In the U.S. beyond just cardiac surgery. CTSO did not provide much in the way of specifics on the call relative to the near-term game plan for a U.S. cardiac surgery trial, although did note that they will be hiring a Chief Scientific Officer to manage the U.S. trial (as well as European studies) and will be recruiting a Cardiac Surgery Advisory Board. The cardiac surgery clinical data generated overseas might be used as support to petition U.S. regulators to initiate a clinical study in this country.
- Partnering for other products: CTSO had mentioned on prior calls that they would look for partners for commercialization of some of their other products – these include HemoDefend (blood purification and storage), ContrastSorb (prevention of CIN), and DrugSorb,(drug detox and overdose) as well as four or five other products that are in the pipeline. This will be an ongoing focus in 2014. CTSO is focused on what they termed “de-risking” these products to make them even more attractive to potential commercialization partners – which includes making enhancements to the products. Further de-risking of HemoDefend may also come from the ABLE (Canada) and RECESS (U.S.) pivotal studies. The studies are attempting to determine whether aged blood may be potentially more toxic than new blood – data from these could be available during the year – and could potentially provide support for use HemoDefend to keep blood fresh. CTSO noted on the call that they have confirmed the regulatory pathway in both the U.S. and E.U. (although mgmt. did not elaborate) for the in-line filter HemoDefend product.
READ THE LATEST FULL RESEARCH REPORT HERE
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning.
By Brian Marckx, CFA